Anavex Life Sciences Stock (NASDAQ: AVXL)

Anavex Life Sciences Stock (NASDAQ:AVXL), Trade Ideas

Anavex Life Sciences

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABVC

AEVA

ARWR

ATXG

AVXL

BREA

CREV

ELTX

ESPR

FWBI

GSX Techedu Inc. American Depositary Shares

GOTU

HALL

IFBD

INSP

LTHM

NEXI

NMRD

ONMD

OPEN

PNST

PRCH

PRSO

SASI

SIDU

SOFI

SPWR

TAOP

TCBP

TDCX

TENX

TPHS

VYGR

YOSH

ZCAR

ZJYL

Shares of  SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette &amp; Woods downgraded rating on the stock.

Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

COLL

JMIA

NAAS

PSTG

TRML

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday.

Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a preliminary non-binding acquisition offer.

TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday

Earnings

Eurozone

Commodities

Global

CORT

LBPH

LMDX

SNES

TSLA

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday.

The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to 14,743.80. The S&amp;P 500 also fell, dropping, 0.66% to 4,738.37.

Crude Oil Down 2%; Tesla Deliveries Top Estimates

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences Corp

Biotech

Health Care

General

Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 35.29 percent increase over losses of $(0.17) per share from the same period last year.

Anavex Life Sciences Q1 EPS $(0.11) Beats $(0.14) Estimate; Cash And Cash Equivalents Of $143.8M

ACLS

ADNT

ALCO

APPS

ARCC

ASGN

ASND

AZTA

BABA

BARK

BERY

BLBD

CDAY

CENT

CENTA

CFLT

CMRE

COTY

CRTO

CSGS

EEFT

ENTA

EQNR

FLNC

FLNG

FORM

FOXA

GEOS

GPRE

GPRO

HAIN

INTR

MCFT

MKSI

MPWR

MSGE

MTRX

NBIX

NOTV

NTGR

NVST

NWSA

OESX

ORLY

OSCR

PAHC

Earnings Scheduled For February 7, 2024

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-07. Here's what investors need to know before the announcement.
Analysts estimate that Anavex Life Sciences will report an earnings per share (EPS) of $-0.14. 
Anavex Life Sciences bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 6.6% increase in the share price the next day.
Here's a look at Anavex Life Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.15</td>
<td>-0.17</td>
<td>-0.19</td>
<td>-0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.12</td>
<td>-0.14</td>
<td>-0.17</td>
<td>-0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.6%</td>
<td>16.69%</td>
<td>3.2%</td>
<td>-6.98%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707246107_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Anavex Life Sciences were trading at $5.36 as of February 05. Over the last 52-week period, shares are down 49.18%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/AVXL/earnings">To track all earnings releases for Anavex Life Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Anavex Life Sciences Earnings Preview

Anavex Life Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NYSE">AVXL</a>) short percent of float has risen 10.79% since its last report. The company recently reported that it has 20.07 million shares sold short, which is 25.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 11.37 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Anavex Life Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1706121917_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Anavex Life Sciences has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Anavex Life Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Anavex Life Sciences's peer group average for short interest as a percentage of float is 14.82%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Anavex Life Sciences's Recent Short Interest

Anavex Life Sciences Announced A Peer-reviewed Publication In Clinical Pharmacology In Drug Development, Findings From The ANAVEX 3-71 First-in-human Study Which Achieved Its Safety Objectives

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) has outperformed the market over the past 5 years by 16.49% on an annualized basis producing an average annual return of 29.4%. Currently, Anavex Life Sciences has a market capitalization of $545.05 million. 
Buying $1000 In AVXL: If an investor had bought $1000 of AVXL stock 5 years ago, it would be worth $3,648.35 today based on a price of $6.64 for AVXL at the time of writing.
<h3>Anavex Life Sciences's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1706020260_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) has outperformed the market over the past 5 years by 15.54% on an annualized basis producing an average annual return of 28.04%. Currently, Anavex Life Sciences has a market capitalization of $500.73 million. 
Buying $1000 In AVXL: If an investor had bought $1000 of AVXL stock 5 years ago, it would be worth $3,441.86 today based on a price of $6.10 for AVXL at the time of writing.
<h3>Anavex Life Sciences's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1705590047_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,400 Today

Anavex Life Sciences Has Initiated FDA-Cleared Placebo-controlled Phase 2 Trial Of ANAVEX3-71 For The Treatment Of Schizophrenia, Which Is Expected To Begin In Q2 2024

The company was granted new U.S. Patent No. 11,839,600 entitled &quot;NEURODEVELOPMENTAL DISORDER THERAPY&quot; from the United States Patent and Trademark Office (USPTO) for its patent application number 17/890,083.

Anavex Life Sciences Reports Grant Of US Patent Covering Blarcamesine (ANAVEX2-73) For Treatment Of Neurodevelopmental Disorders

Shares of SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>) fell sharply during Wednesday&rsquo;s session after Keefe, Bruyette &amp; Woods <a href="https://www.benzinga.com/news/24/01/36470244/sofi-stock-is-sliding-wednesday-whats-going-on">downgraded rating on the stock</a>.
Keefe, Bruyette &amp; Woods analyst Michael Perito downgraded SoFi from a Market Perform rating to an Underperform rating and lowered the price target from $7.50 to $6.50, citing recent outperformance and a change in the analyst&#39;s model.
SoFi Technologies shares dipped 12.8% to $8.41 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>NexImmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nexi#NASDAQ">NEXI</a>) shares rose 150.8% to $6.14 after gaining over 6% on Tuesday.</li>
<li>Trinity Place Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tphs#NYSE">TPHS</a>) rose gained 62.6% to $0.1857. The company reported in 8K Filing, <a href="https://www.benzinga.com/money/mortgage-lenders-no-tax-returns/">mortgage</a> lender agreed to extend the mortgage loan forbearance period to Jan. 31, 2024.</li>
<li>Sigma Additive Solutions, Inc.(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sasi#NASDAQ">SASI</a>) gained 60.3% to $4.65. Sigma Additive Solutions, announced in an 8-K Filing, the approval of the issuance of the shares of common stock in exchange for all the capital stock of NextTrip Holdings.</li>
<li>ABVC BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abvc#NASDAQ">ABVC</a>) jumped 58.3% to $1.90. ABVC BioPharma and its subsidiary received $460 million from AiBtl BioPharma as the first milestone payment of global licensing fees.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) rose 48.4% to $10.35. Sidus Space secured NOAA approval to provide imaging services to government and commercial customers.</li>
<li>Brera Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brea#NASDAQ">BREA</a>) shares gained 32.8% to $0.97.</li>
<li>First Wave BioPharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fwbi#NASDAQ">FWBI</a>) shares gained 31.2% to $5.01. Roth MKM raised price target on the stock to $40.</li>
<li>Elicio Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eltx#NASDAQ">ELTX</a>) gained 29% to $7.65.</li>
<li>TDCX Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdcx#NYSE">TDCX</a>) gained 28% to $6.18 after it disclosed receiving a preliminary non-binding acquisition offer.</li>
<li>Ucommune International Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/uk#NASDAQ">UK</a>) shares gained 27% to $5.14 after gaining 9% on Tuesday.</li>
<li>OneMedNet Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onmd#NASDAQ">ONMD</a>) jumped 24% to $0.93. The company said OneMedNet iRWD(TM) is now available on AWS Data Exchange.</li>
<li>Hongli Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlp#NASDAQ">HLP</a>) rose 23.6% to $2.68.</li>
<li>Aeva Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aeva#NYSE">AEVA</a>) gained 19.3% to $0.8715. Aeva said that one of the top global automotive OEMs has selected Aeva as its Tier 1 LiDAR supplier for its series production vehicle program.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) shares jumped 16.2% to $15.17. Dyne Therapeutics released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) rose 16.1% to $10.45.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crev#NASDAQ">CREV</a>) rose 15.8% to $27.01.</li>
<li>Gaotu Techedu Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) rose 15.1% to $3.7601.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) gained 7% to $33.17. Arrowhead Pharmaceuticals reported pricing of offering of 15.79 million shares at $28.50 per share.</li>
<li>Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) gained 6.5% to $6.44. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained Anavex Life Sciences with a Buy and lowered the price target from $54 to $40.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>E-Home Household Service Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ejh#NASDAQ">EJH</a>) fell 60.2% to $1.52.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares fell 37.1% to $0.2886. RiskOn International, in partnership with Meetkai, announced the launch of &quot;askROI.com.&quot;</li>
<li>Infobird Co., Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ifbd#NASDAQ">IFBD</a>) tumbled 35% to $0.8922.</li>
<li>Pinstripes Holdings Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pnst#NYSE">PNST</a>) shares fell 29.1% to $9.44 after surging 22% on Tuesday. Pinstripes and Banyan Acquisition Corporation announced they have closed their previously announced business combination, which was approved by Banyan&rsquo;s stockholders at a meeting on Dec. 27, 2023.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) dipped 25.5% to $2.1750 after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo Co., Ltd.</li>
<li>Nemaura Medical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmrd#NASDAQ">NMRD</a>) fell 25.5% to $0.1403.</li>
<li>Peraso Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prso#NASDAQ">PRSO</a>) fell 22.4% to $7.33.</li>
<li>Taoping Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/taop#NASDAQ">TAOP</a>) fell 21.1% to $1.4830.</li>
<li>Kelso Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kiq#NASDAQ">KIQ</a>) fell 20.8% to $0.1814.</li>
<li>The OLB Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olb#NASDAQ">OLB</a>) declined 20.7% to $0.8001.</li>
<li>Signing Day Sports, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sgn#NYSE">SGN</a>) fell 20.7% to $0.8345 after declining around 7% on Tuesday.</li>
<li>Hallmark Financial Services, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hall#NASDAQ">HALL</a>) declined 20.6% to $0.9913.</li>
<li>TC Biopharm (Holdings) Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcbp#NASDAQ">TCBP</a>) fell 18.5% to $2.55. TC BioPharm announced additional cost reduction steps to improve financial standing and streamline efficiencies.</li>
<li>Tenax Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tenx#NASDAQ">TENX</a>) dipped 16.5% to $17.35.</li>
<li>Jin Medical International Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zjyl#NASDAQ">ZJYL</a>) fell 15.3% to $216.00.</li>
<li>Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) fell 13.1% to $2.6405.</li>
<li>Yoshiharu Global Co. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yosh#NASDAQ">YOSH</a>) shares fell 11.4% to $6.01 after gaining 25% on Tuesday.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) dipped 11.3% to $4.3250.</li>
<li>Sunrun Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/run#NASDAQ">RUN</a>) fell 11.1% to $17.30.</li>
<li>Addentax Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atxg#NASDAQ">ATXG</a>) shares fell 10.8% to $1.3199.</li>
<li>Inspire Medical Systems, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/insp#NYSE">INSP</a>) fell 10% to $169.13.</li>
<li>Livent Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lthm#NASDAQ">LTHM</a>) fell 9.8% to $16.26.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) fell 9.6% to $8.30 after jumping 52% on Tuesday.</li>
<li>Zoomcar Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zcar#NASDAQ">ZCAR</a>) shares fell 9% to $2.72 after dipping around 19% on Tuesday.</li>
<li>Xerox Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xrx#NYSE">XRX</a>) fell 8.8% to $16.44.</li>
<li>Kohl&#39;s Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kss#NYSE">KSS</a>) dipped 8.4% to $25.67.</li>
<li>UniFirst Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unf#NYSE">UNF</a>) fell 8.4% to $165.16 following first-quarter results.</li>
<li>Opendoor Technologies Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/open#NASDAQ">OPEN</a>) fell 7.9% to $3.9409. JMP Securities analyst Nicholas Jones maintained Opendoor Technologies with an Outperform and raised the price target from $3.5 to $5.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36470306/ethereum-falls-below-2-300-bonk-becomes-top-loser"> Ethereum Falls Below $2,300; Bonk Becomes Top Loser</a>

Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday.
Shares of TDCX Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdcx#NYSE">TDCX</a>) rose sharply during Wednesday&rsquo;s session after it disclosed receiving a preliminary non-binding acquisition offer.
The company got an acquisition offer from Laurent Junique, its Founder, Executive Chairman, Director, and CEO, for a purchase price of $6.60/share or ADS in cash. The company has created a special committee of the Board, comprised solely of independent and disinterested directors, to consider the proposal letter dated Jan. 2, 2024.
TDCX shares surged 28% to $6.18 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) shares jumped 16.2% to $15.17. Dyne Therapeutics released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) gained 16.1% to $10.45.</li>
<li>Gaotu Techedu Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gotu#NYSE">GOTU</a>) climbed 15.1% to $3.7601.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) surged 7% to $33.17. Arrowhead Pharmaceuticals reported pricing of offering of 15.79 million shares at $28.50 per share.</li>
<li>NaaS Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/naas#NASDAQ">NAAS</a>) rose 6.9% to $1.54.</li>
<li>Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) rose 6.5% to $6.44. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained Anavex Life Sciences with a Buy and lowered the price target from $54 to $40.</li>
<li>Collegium Pharmaceutical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coll#NASDAQ">COLL</a>) rose 6% to $33.11.</li>
<li>Jumia Technologies AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jmia#NYSE">JMIA</a>) gained 5.4% to $3.5412. Morgan Stanley analyst Luke Holbrook upgraded Jumia Technologies from Underweight to Equal-Weight and raised the price target from $3 to $3.6.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) climbed 5.3% to $32.66. Arrowhead Pharmaceuticals reported pricing of offering of 15.79 million shares at $28.50 per share.</li>
<li>Pure Storage, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pstg#NYSE">PSTG</a>) rose 5.1% to $36.58 after it was announced the company will join the S&amp;P MidCap 400.</li>
<li>Tourmaline Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/trml#NASDAQ">TRML</a>) gained 5% to $27.83.</li>
<li>TAL Education Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tal#NYSE">TAL</a>) rose 4.9% to $12.37.</li>
<li>Suncor Energy Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/su#NYSE">SU</a>) gained 4.2% to $33.45.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36464063/how-to-earn-500-a-month-from-apple-stock-following-tuesdays-slide"> How To Earn $500 A Month From Apple Stock Following Tuesday&#39;s Slide </a>

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and lowers the price target from $54 to $40.

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Anavex Life Sciences, Lowers Price Target to $40

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday.
The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to 14,743.80. The S&amp;P 500 also fell, dropping, 0.66% to 4,738.37.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36423038/how-to-earn-500-a-month-from-annaly-capital-management-stock"> How To Earn $500 A Month From Annaly Capital Management Stock</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
Health care shares rose by 1.8% on Tuesday.
In trading on Tuesday, information technology shares fell by 2.3%.
&nbsp;
<h3>Top Headline</h3>
Tesla Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) reported production and delivery <a href="https://www.benzinga.com/markets/equities/24/01/36451335/tesla-stock-takes-off-premarket-after-q4-deliveries-exceed-expectation-full-year-sales-exceed-1-">data for the fourth quarter</a>.
Tesla said it produced 494,989 vehicles in the fourth quarter, up from 430,488 in the third quarter. The EV maker delivered 484,507 vehicles in the quarter, up from 435,059 in the previous quarter,&nbsp;exceeded the company-compiled consensus of 480,483 units.
&nbsp;
<h3>Equities Trading UP</h3>
Longboard Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbph#NASDAQ">LBPH</a>) shares shot up 205% to $18.39 after the company announced topline data from the PACIFIC Study evaluating bexicaserin in patients with Developmental and Epileptic Encephalopathies.
Shares of Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) got a boost, surging 24% to $10.48 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington&#39;s disease and spinal muscular atrophy.
SenesTech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snes#NASDAQ">SNES</a>) shares were also up, gaining 34% to $1.6982 after the company announced the expansion of its distribution agreement with Pesterminators to include the deployment of Evolve and extend its territory into the UAE.
&nbsp;
<h3>Equities Trading DOWN</h3>
Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) shares dropped 34% to $6.16 after the company provided an update on Rett Syndrome program.
Shares of LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) were down 28% to $0.0465. LumiraDx agreed to sell its point-of-care technology platform to Roche.
Corcept Therapeutics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) was down, falling 28% to $23.53 after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept&#39;s U.S. Patents 10,195,214 and 10,842,800.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36426899/top-4-tech-and-telecom-stocks-that-may-fall-off-a-cliff-in-q4"> Top 4 Tech And Telecom Stocks That May Fall Off A Cliff In Q4</a>
&nbsp;
<h3>Commodities</h3>
In commodity news, oil traded down 2.1% to $70.17&nbsp;while gold traded up 0.1% at $2,074.40.
Silver traded down 0.3% to $24.015 on Tuesday while copper fell 0.1% to $3.8875.
&nbsp;
<h3>Euro zone</h3>
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.11%, London&rsquo;s FTSE 100 fell 0.15% while Spain&rsquo;s IBEX 35 Index rose 0.79% The German DAX rose 0.11% French CAC 40 fell 0.16% while Italy&rsquo;s FTSE MIB Index rose 0.57%.
Bank lending to households in the Eurozone increased by 0.5% year-over-year to EUR 6.87 trillion in November. The HCOB Eurozone manufacturing PMI rose to 44.4 in December, from the preliminary level of 44.2.
The S&amp;P Global UK manufacturing PMI was revised lower to 46.2 in December from the preliminary estimate of 46.4, while German manufacturing PMI was revised higher to 43.3 in December versus a preliminary reading of 43.1. The HCOB France manufacturing PMI declined to 42.1 in December versus 42.9 a month ago.
&nbsp;
<h3>Asia Pacific Markets</h3>
Asian markets closed lower on Tuesday, with Hong Kong&rsquo;s Hang Seng Index falling 1.52% and China&rsquo;s Shanghai Composite Index falling 0.43%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.53%.
The official NBS non-manufacturing PMI for China rose to 50.4 in December from November&#39;s reading of 50.2, while manufacturing PMI fell to 49.0 in from 49.4. Singapore&rsquo;s GDP increased by 2.8% year-over-year in the fourth quarter versus a revised 1.0% increase in the third quarter. The Judo Bank Australia manufacturing PMI fell to 47.6 in December versus a preliminary reading of 47.8.
&nbsp;
<h3>Economics</h3>
The S&amp;P Global manufacturing PMI was revised lower to 47.9 in December versus a preliminary level of 48.2, and versus November&rsquo;s level of 49.4.
Construction spending rose by 0.4% month-over-month to an annual rate of $2,050.1 billion in November.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36426898/accenture-lyft-and-2-other-stocks-insiders-are-selling"> Accenture, Lyft And 2 Other Stocks Insiders Are Selling</a>
&nbsp;

Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbph#NASDAQ">LBPH</a>) rose sharply during Tuesday&rsquo;s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs).
Longboard Pharmaceuticals shares jumped 199.7% to $18.07 on Tuesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Akso Health Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ahg#NASDAQ">AHG</a>) surged 85% to $1.2946.</li>
<li>Polished.com Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pol#NYSE">POL</a>) gained 45% to $8.77.</li>
<li>Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) jumped 40% to $7.42.</li>
<li>Cue Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlth#NASDAQ">HLTH</a>) gained 36.8% to $0.2224 after falling 42% on Friday.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) surged 34% to $11.38 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington&#39;s disease and spinal muscular atrophy.</li>
<li>RiskOn International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/roi#NASDAQ">ROI</a>) shares climbed 33.5% to $0.4450 after gaining around 17% on Friday. RiskOn International recently said it expects to announce its new generative AI platform and unveil a principal technology partner on Jan. 3.</li>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares gained 33.4% to $1.01. Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses.</li>
<li>SenesTech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snes#NASDAQ">SNES</a>) gained 22.2% to $1.56. SenesTech announced the expansion of its distribution agreement with Pesterminators Pvt Ltd to include the deployment of EvolveTM.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) jumped 17.1% to $4.31. Brooge Energy recently announced that it reached a settlement with the SEC where it agreed to pay a $5 million penalty and cease any future violations.</li>
<li>Lyell Immunopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lyel#NASDAQ">LYEL</a>) gained 16.9% to $2.26.</li>
<li>Wheels Up Experience Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/up#NYSE">UP</a>) surged 16.9% to $4.01.</li>
<li>BTCS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcs#NASDAQ">BTCS</a>) shares rose 14.1% to $1.8593 amid strength in Bitcoin.</li>
<li>Allogene Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allo#NASDAQ">ALLO</a>) gained 12% to $3.59.</li>
<li>Precigen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pgen#NASDAQ">PGEN</a>) rose 11.9% to $1.50.</li>
<li>Argo Blockchain plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arbk#NASDAQ">ARBK</a>) shares gained 11.8% to $4.18 after falling 8% on Friday.</li>
<li>MicroStrategy Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>) gained 11.4% to $703.40 after Bitcoin rose above $45,000.</li>
<li>Kiniksa Pharmaceuticals, Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/knsa#NASDAQ">KNSA</a>) rose 10.8% to $19.43.</li>
<li>MannKind Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnkd#NASDAQ">MNKD</a>) gained 9.9% to $4.0001. MannKind sold a 1% royalty in net sales of Tyvaso DPI (Treprostinil) inhalation powder in exchange for up to $200 million, including the purchase price of $150 million and an additional potential milestone payment of up to $50 million.</li>
<li>Moderna, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrna#NASDAQ">MRNA</a>) climbed 9.8% to $109.18 after Openheimer upgraded the stock from Perform to Outperform.</li>
<li>Alpha and Omega Semiconductor Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aosl#NASDAQ">AOSL</a>) gained 8.8% to $28.36. B. Riley Securities analyst Craig Ellis upgraded Alpha &amp; Omega from Neutral to Buy and raised the price target from $28 to $34.</li>
<li>Hut 8 Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hut#NASDAQ">HUT</a>) gained 6.3% to $14.19 amid strength in Bitcoin.</li>
<li>CleanSpark, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/clsk#NASDAQ">CLSK</a>) gained 6.2% to $11.71 amid strength in Bitcoin.</li>
<li>Marathon Digital Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mara#NASDAQ">MARA</a>) shares jumped 6% to $24.88 amid strength in Bitcoin.</li>
<li>Riot Platforms, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/riot#NASDAQ">RIOT</a>) surged 5.3% to $16.29 mid strength in Bitcoin.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>RenovoRx, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rnxt#NASDAQ">RNXT</a>) shares tumbled 29.9% to $1.6050.</li>
<li>China SXT Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtc#NASDAQ">SXTC</a>) fell 28.8% to $2.8250 after gaining 92% on Friday.</li>
<li>Sentage Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sntg#NASDAQ">SNTG</a>) shares fell 28.8% to $3.56 after jumping over 182% on Friday.</li>
<li>LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) fell 28.7% to $0.0459. LumiraDx agreed to sell its point-of-care technology platform to Roche.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) fell 26.3% to $23.93 after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept&#39;s U.S. Patents 10,195,214 and 10,842,800.</li>
<li>Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) shares fell 26.2% to $6.88 after the company provided an update on Rett Syndrome program.</li>
<li>Mobix Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mobx#NASDAQ">MOBX</a>) fell 25.6% to $2.9895.</li>
<li>FLJ Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/flj#NASDAQ">FLJ</a>) shares fell 21% to $1.58 after surging 48% on Friday.</li>
<li>Aditxt, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adtx#NASDAQ">ADTX</a>) shares fell 21% to $5.24 after jumping around 38% on Friday.</li>
<li>Vertex Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtnr#NASDAQ">VTNR</a>) declined 20.1% to $2.7069 after the company announced it amended its existing term loan agreement, which provides for an incremental $50 million in borrowings to the company.</li>
<li>Vast Renewables Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vste#NASDAQ">VSTE</a>) fell 17.2% to $4.14.</li>
<li>JOYY Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yy#NASDAQ">YY</a>) fell 16.2% to $33.27 after the company announced it received a written notice from an affiliate of Baidu purporting to terminate the Share Purchase Agreement, dated Nov. 16, 2020.</li>
<li>GoodRx Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdrx#NASDAQ">GDRX</a>) dipped 15.5% to $5.66 after B of A Securities downgraded the stock from Buy to Underperform and lowered its price target from $8 to $4.5.</li>
<li>China Green Agriculture, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cga#NYSE">CGA</a>) shares fell 15.2% to $2.57 after jumping over 59% on Friday.</li>
<li>KORE Group Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/kore#NYSE">KORE</a>) shares fell 13.8% to $0.8451 after jumping over 40% on Friday.</li>
<li>Aurora Innovation, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aur#NASDAQ">AUR</a>) fell 13.8% to $3.7605 after the company filed for an $850 million mixed securities shelf offering.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tblt#NASDAQ">TBLT</a>) declined 13.5% to $8.86.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) fell 12.5% to $8.63.</li>
<li>Amprius Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ampx#NYSE">AMPX</a>) fell 11.5% to $4.68.</li>
<li>PureTech Health plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtc#NASDAQ">PRTC</a>) fell 9.6% to $24.79.</li>
<li>Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) dipped 9.1% to $21.34 after the company reported delivery and production figures for 2023.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) fell 7.7% to $1.6141.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36448544/top-5-health-care-stocks-that-could-lead-to-your-biggest-gains-in-january"> Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January</a>

ADTX

ALLO

AMPX

AOSL

ARBK

BROG

BTCS

BTDR

CLSK

DOGZ

GDRX

HLTH

KNSA

KORE

LYEL

MARA

MNKD

MOBX

MRNA

MSTR

PGEN

PRTC

RIOT

RIVN

RNXT

SNGX

SNTG

SXTC

TBLT

VSTE

VTNR

Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longboard Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) shares moved upwards by 200.7% to $18.13 during Tuesday's regular session. The company's market cap stands at $432.5 million. </li>
<li>NGM Biopharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGM#NASDAQ">NGM</a>) stock moved upwards by 49.01% to $1.28. The market value of their outstanding shares is at $105.8 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares increased by 37.27% to $3.42. The market value of their outstanding shares is at $70.1 million. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares moved upwards by 33.07% to $1.69. The company's market cap stands at $1.2 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) shares moved upwards by 29.29% to $0.21. The company's market cap stands at $32.4 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) shares moved upwards by 27.32% to $0.91. The market value of their outstanding shares is at $71.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares fell 34.5% to $6.09 during Tuesday's regular session. The company's market cap stands at $500.3 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock decreased by 29.98% to $2.78. The company's market cap stands at $1.5 million. </li>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) stock declined by 28.19% to $23.32. The market value of their outstanding shares is at $2.4 billion. </li>
<li>LumiraDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMDX#NASDAQ">LMDX</a>) stock decreased by 25.6% to $0.05. The company's market cap stands at $14.9 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) shares declined by 24.9% to $1.72. The company's market cap stands at $18.3 million. </li>
<li>Aditxt (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares declined by 23.08% to $5.1. The market value of their outstanding shares is at $2.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

VNRX

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday.
The Dow traded up 0.13% to 37,739.18 while the NASDAQ fell 1.29% to 14,818.23. The S&amp;P 500 also fell, dropping, 0.45% to 4,748.51.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36423038/how-to-earn-500-a-month-from-annaly-capital-management-stock"> How To Earn $500 A Month From Annaly Capital Management Stock</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Energy shares rose by 1.5% on Tuesday.
In trading on Tuesday, information technology shares fell by 2.2%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Rivian Automotive Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) reported vehicle production and delivery totals for the fourth quarter.
The company produced 17,541 vehicles (vs. 10,020) at its manufacturing facility in Normal, Illinois, and delivered 13,972 cars in the fourth quarter. The latest-quarter delivery was below the third-quarter figure of 15,564 and below analysts&#39; estimate of 14,430, as per Reuters.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Longboard Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbph#NASDAQ">LBPH</a>) shares shot up 194% to $17.70 after the company announced topline data from the PACIFIC Study evaluating bexicaserin in patients with Developmental and Epileptic Encephalopathies.
Shares of Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) got a boost, surging 25% to $10.54 after the company announced a strategic collaboration and capsid license agreement with Novartis to advance potential gene therapies for Huntington&#39;s disease and spinal muscular atrophy.
SenesTech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snes#NASDAQ">SNES</a>) shares were also up, gaining 35% to $1.7099 after the company announced the expansion of its distribution agreement with Pesterminators to include the deployment of Evolve and extend its territory into the UAE.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) shares dropped 33% to $6.25 after the company provided an update on Rett Syndrome program.
Shares of LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) were down 26% to $0.0475. LumiraDx agreed to sell its point-of-care technology platform to Roche.
Corcept Therapeutics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) was down, falling 26% to $23.97 after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept&#39;s U.S. Patents 10,195,214 and 10,842,800.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36426899/top-4-tech-and-telecom-stocks-that-may-fall-off-a-cliff-in-q4"> Top 4 Tech And Telecom Stocks That May Fall Off A Cliff In Q4</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 1.5% to $70.56 while gold traded up 0.1% at $2,073.80.
Silver traded down 0.2% to $24.035 on Tuesday while copper fell 0.6% to $3.8685.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.16%, London&rsquo;s FTSE 100 fell 0.28% while Spain&rsquo;s IBEX 35 Index rose 0.78% The German DAX rose 0.09% French CAC 40 fell 0.26% while Italy&rsquo;s FTSE MIB Index rose 0.57%.
Bank lending to households in the Eurozone increased by 0.5% year-over-year to EUR 6.87 trillion in November. The HCOB Eurozone manufacturing PMI rose to 44.4 in December, from the preliminary level of 44.2.
The S&amp;P Global UK manufacturing PMI was revised lower to 46.2 in December from the preliminary estimate of 46.4, while German manufacturing PMI was revised higher to 43.3 in December versus a preliminary reading of 43.1. The HCOB France manufacturing PMI declined to 42.1 in December versus 42.9 a month ago.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Tuesday, with Hong Kong&rsquo;s Hang Seng Index falling 1.52% and China&rsquo;s Shanghai Composite Index falling 0.43%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.53%.
The official NBS non-manufacturing PMI for China rose to 50.4 in December from November&#39;s reading of 50.2, while manufacturing PMI fell to 49.0 in from 49.4. Singapore&rsquo;s GDP increased by 2.8% year-over-year in the fourth quarter versus a revised 1.0% increase in the third quarter. The Judo Bank Australia manufacturing PMI fell to 47.6 in December versus a preliminary reading of 47.8.
&nbsp;
<h3>Economics</h3>
&nbsp;
The S&amp;P Global manufacturing PMI was revised lower to 47.9 in December versus a preliminary level of 48.2, and versus November&rsquo;s level of 49.4.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36426898/accenture-lyft-and-2-other-stocks-insiders-are-selling"> Accenture, Lyft And 2 Other Stocks Insiders Are Selling</a>

Dow Turns Higher; Anavex Life Sciences Shares Plunge

U.S. stocks traded mostly lower, with the Nasdaq Composite falling around 200 points on Tuesday.
Shares of Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) fell sharply during Tuesday&rsquo;s session after the company reported delivery and <a href="https://www.benzinga.com/markets/equities/24/01/36452278/why-rivian-automotive-shares-are-tumbling-today">production figures for 2023</a>.
The company produced 17,541 vehicles (vs. 10,020) at its manufacturing facility in Normal, Illinois, and delivered 13,972 cars in the fourth quarter. The recent-quarter delivery was below the third-quarter figure of 15,564 and below analysts&#39; estimate of 14,430, as per Reuters.
Rivian Automotive shares dipped 9.1% to $21.34 on Tuesday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>Corcept Therapeutics Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) shares dipped 26.3% to $23.93 after the company announced the Court for the District of New Jersey issued a decision that Teva Pharmaceuticals does not infringe any asserted claims of Corcept&#39;s U.S. Patents 10,195,214 and 10,842,800.</li>
<li>Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) shares tumbled 26.2% to $6.88 after the company provided an update on Rett Syndrome program.</li>
<li>Vertex Energy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtnr#NASDAQ">VTNR</a>) dipped 20.1% to $2.7069 after the company announced it amended its existing term loan agreement, which provides for an incremental $50 million in borrowings to the company.</li>
<li>JOYY Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/yy#NASDAQ">YY</a>) declined 16.2% to $33.27 after the company announced it received a written notice from an affiliate of Baidu purporting to terminate the Share Purchase Agreement, dated Nov. 16, 2020.</li>
<li>GoodRx Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gdrx#NASDAQ">GDRX</a>) shares tumbled 15.5% to $5.66 after B of A Securities downgraded the stock from Buy to Underperform and lowered its price target from $8 to $4.5.</li>
<li>Aurora Innovation, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aur#NASDAQ">AUR</a>) shares declined 13.8% to $3.7605 after the company filed for an $850 million mixed securities shelf offering.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tblt#NASDAQ">TBLT</a>) fell 13.5% to $8.86.</li>
<li>Bitdeer Technologies Group (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btdr#NASDAQ">BTDR</a>) tumbled 12.5% to $8.63.</li>
<li>AST SpaceMobile, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asts#NASDAQ">ASTS</a>) fell 11.4% to $5.34.</li>
<li>Amprius Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ampx#NASDAQ">AMPX</a>) declined 11.2% to $4.70.</li>
<li>MiMedx Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdxg#NASDAQ">MDXG</a>) dipped 10.9% to $7.82 after the company announced it received a Warning Letter from FDA for AXIOFILL. The company also reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin.</li>
<li>Pulse Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/plse#NASDAQ">PLSE</a>) fell 10.7% to $10.93. Pulse Biosciences filed 510(k) submission with the US FDA for its CellFX nsPFA cardiac clamp.</li>
<li>Fusion Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fusn#NASDAQ">FUSN</a>) declined 10.5% to $8.60.</li>
<li>Savara Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/svra#NASDAQ">SVRA</a>) fell 9.7% to $4.24.</li>
<li>PureTech Health plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prtc#NASDAQ">PRTC</a>) dipped 9.6% to $24.79.</li>
<li>VinFast Auto Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vfs#NASDAQ">VFS</a>) fell 8.9% to $7.63. VinFast has officially signed agreements with five dealers in four states across the U.S.</li>
<li>America&#39;s Car-Mart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmt#NASDAQ">CRMT</a>) fell 8% to $69.70. Stephens &amp; Co. downgraded America&#39;s Car-Mart from Overweight to Equal-Weight.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) shares declined 7.7% to $1.6141.</li>
<li>TAL Education Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tal#NYSE">TAL</a>) fell 7.4% to $11.69.</li>
<li>Arm Holdings plc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/arm#NYSE">ARM</a>) fell 6.3% to $70.42.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36452122/this-analyst-with-84-accuracy-rate-sees-around-13-upside-in-darden-restaurants-here-are-"> This Analyst With 84% Accuracy Rate Sees Around 13% Upside In Darden Restaurants - Here Are 5 Stock Picks For 2023 From Wall Street&#39;s Most Accurate Analysts</a>

ASTS

CRMT

FUSN

MDXG

PLSE

SVRA

Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday

<a href="https://www.statnews.com/2024/01/02/anavex-rett-study-failure/">https://www.statnews.com/2024/01/02/anavex-rett-study-failure/</a>
It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett Syndrome.
The negative study outcome was <a href="https://www.statnews.com/2023/08/10/anavex-blarcamesine-rett-syndrome-clinical-trials/">never in doubt</a>, so the only surprise from Tuesday's announcement was the company's lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.
Anavex shares fell 31% to $6 in early trading. The company's only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in <a href="https://www.statnews.com/2022/12/02/an-anavex-study-spin-job-sullies-an-otherwise-spectacular-alzheimers-conference/">Alzheimer's disease</a> and Parkinson's disease. Yet even with Tuesday's drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.
 &nbsp;

"A Single Drug And Multiple Study Failures Leave Anavex With Nothing But Cash" - StatNews

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.28% to 37,584.41 while the NASDAQ fell 1.35% to 14,808.88. The S&amp;P 500 also fell, dropping, 0.72% to 4,735.41.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/23/12/36423038/how-to-earn-500-a-month-from-annaly-capital-management-stock"> How To Earn $500 A Month From Annaly Capital Management Stock</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Energy shares rose by 1.1% on Tuesday.
In trading on Tuesday, information technology shares fell by 1.8%.
<h3>
Top Headline</h3>
&nbsp;
The S&amp;P Global manufacturing PMI was revised lower to 47.9 in December versus a preliminary level of 48.2, and versus November&rsquo;s level of 49.4.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Longboard Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lbph#NASDAQ">LBPH</a>) shares shot up 198% to $17.95 after the company announced topline data from the PACIFIC Study evaluating bexicaserin in patients with Developmental and Epileptic Encephalopathies.
Shares of Cue Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlth#NASDAQ">HLTH</a>) got a boost, surging 42% to $0.2301 after falling 42% on Friday.
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares were also up, gaining 36% to $1.0300. 
Soligenix announced publication demonstrating complete protection against filovirus disease in nonhuman primate models of ebola and marburg viruses.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Anavex Life Sciences Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avxl#NASDAQ">AVXL</a>) shares dropped 32% to $6.31 after the company provided an update on Rett Syndrome program.
Shares of LumiraDx Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lmdx#NASDAQ">LMDX</a>) were down 34% to $0.0428. LumiraDx agreed to sell its point-of-care technology platform to Roche.
China SXT Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sxtc#NASDAQ">SXTC</a>) was down, falling 29% to $2.82 after gaining 92% on Friday.
Also Check This Out:<a href="https://www.benzinga.com/news/23/12/36426899/top-4-tech-and-telecom-stocks-that-may-fall-off-a-cliff-in-q4"> Top 4 Tech And Telecom Stocks That May Fall Off A Cliff In Q4</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.1% to $71.72 while gold traded up 0.3% at $2,078.40.
Silver traded up 0.5% to $24.205 on Tuesday while copper fell 0.6% to $3.8665.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mostly higher today. The eurozone&rsquo;s STOXX 600 fell 0.3%, London&rsquo;s FTSE 100 fell 0.4% while Spain&rsquo;s IBEX 35 Index rose 0.6% The German DAX fell 0.1% French CAC 40 fell 0.5% while Italy&rsquo;s FTSE MIB Index rose 0.3%.
Bank lending to households in the Eurozone increased by 0.5% year-over-year to EUR 6.87 trillion in November. The HCOB Eurozone manufacturing PMI rose to 44.4 in December, from the preliminary level of 44.2.
The S&amp;P Global UK manufacturing PMI was revised lower to 46.2 in December from the preliminary estimate of 46.4, while German manufacturing PMI was revised higher to 43.3 in December versus a preliminary reading of 43.1. The HCOB France manufacturing PMI declined to 42.1 in December versus 42.9 a month ago.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed lower on Tuesday, with Hong Kong&rsquo;s Hang Seng Index falling 1.52% and China&rsquo;s Shanghai Composite Index falling 0.43%. India&rsquo;s S&amp;P BSE Sensex, meanwhile, fell 0.53%.
The official NBS non-manufacturing PMI for China rose to 50.4 in December from November&#39;s reading of 50.2, while manufacturing PMI fell to 49.0 in from 49.4. Singapore&rsquo;s GDP increased by 2.8% year-over-year in the fourth quarter versus a revised 1.0% increase in the third quarter. The Judo Bank Australia manufacturing PMI fell to 47.6 in December versus a preliminary reading of 47.8.
&nbsp;
<h3>Economics</h3>
&nbsp;
The S&amp;P Global manufacturing PMI was revised lower to 47.9 in December versus a preliminary level of 48.2, and versus November&rsquo;s level of 49.4.
Now Read This: <a href="https://www.benzinga.com/news/23/12/36426898/accenture-lyft-and-2-other-stocks-insiders-are-selling"> Accenture, Lyft And 2 Other Stocks Insiders Are Selling</a>
&nbsp;

Dow Down 100 Points; US Manufacturing PMI Falls In December

Overall market sentiment has been high on Anavex Life Sciences Corp (AVXL)  stock lately. AVXL receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Anavex Life Sciences Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AVXL!See Full AVXL Report

Should You Buy Anavex Life Sciences Corp (AVXL) Stock After it Is Higher By 7.77% in a Week?

Anavex Life Sciences Q1 2024 Earnings Preview

Anavex Life Sciences GAAP EPS of -$0.11 beats by $0.04

JonesTrading analyst Soumit Roy maintained a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of $25.00. So...

Buy Rating Affirmed for Anavex Life Sciences Amid Positive Alzheimer's Program Outlook and Financial Stability